| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 107.2 | 74.4 |
| Net income | 11.3 | 0.6 |
| EPS (diluted, $ a share) | $0.06 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +1718.0% |
|---|---|
| Revenue, year on year | +44.2% |
| Operating margin | 15.8% |
10-Q filed with the SEC, NASDAQ: XERS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Xeris Biopharma Holdings, Inc.: key numbers
- Share price
- $16.70Close, Nov 16
- Market cap
- $3.05B
- Shares outstanding
- 182.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xeris Biopharma Holdings, Inc.
All →Xeris Biopharma Holdings Insider Kevin McCulloch Sells $312K of Stock
Kevin McCulloch sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $12.49 a share, worth $312K in total on Nov 5, 2026. Shares held after the trade: 1,559,208 (-1.6%).
- Value
- $312K
- Shares
- 25,000
- Price
- $12.49
- Holding change
- -1.6%
- Trade date
- Nov 5, 2026
Xeris Biopharma Holdings Earnings Call: Key Takeaways
Xeris Biopharma delivered a strong Q3 with 44% revenue growth, significantly raising 2030 revenue targets to over $1 billion driven by Recorlev momentum.
- Call
- Nov 5, 2026, 8:30 AM ET
Xeris Biopharma Holdings Financial Results
Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.
“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”
John Shannon, Chairman and Chief Executive Officer
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
John Shannon, Chairman and Chief Executive Officer
Xeris Biopharma Holdings Insider Steven Pieper Sells $51.2K of Stock
Steven Pieper sold 5,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $51.2K in total on Nov 2, 2026. Shares held after the trade: 1,346,053 (-0.4%).
- Value
- $51.2K
- Shares
- 5,000
- Price
- $10.23
- Holding change
- -0.4%
- Trade date
- Nov 2, 2026
Xeris Biopharma Holdings Insider Beth Hecht Sells $256K of Stock
Beth Hecht sold 25,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $256K in total on Nov 2, 2026. Shares held after the trade: 1,086,130 (-2.2%).
- Value
- $256K
- Shares
- 25,000
- Price
- $10.23
- Holding change
- -2.2%
- Trade date
- Nov 2, 2026
Xeris Biopharma Holdings Insider Kevin McCulloch Sells $153K of Stock
Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. at $10.23 a share, worth $153K in total on Nov 2, 2026. Shares held after the trade: 1,584,208 (-0.9%).
- Value
- $153K
- Shares
- 15,000
- Price
- $10.23
- Holding change
- -0.9%
- Trade date
- Nov 2, 2026